An Implementer’s Guide to the Tenofovir Disoproxil Fumarate-Lamivudine Dolutegravir (TLD) Transition (Nov 20, 2019)

An Implementer’s Guide to the Tenofovir Disoproxil Fumarate-Lamivudine Dolutegravir (TLD) Transition

Objective: This best practice symposium provided a forum for National Department of Health, partners and local stakeholders to interact with counterparts from regional countries (Botswana, Malawi, Zambia and Malawi) to discuss experiences and showcase strategies and plans that will enable the roll out of Dolutegravir and to discuss strategies for monitoring outcomes in patients exposed to TLD.